Jeff Taylor writes, " I haven't written in a while. Perhaps a few years ago you recall that I pointed GenVec(GNVC - Get Report) out to you. I have a little experience here. My take is this licensing deal with Novartis(NVS) for hearing loss is just a bonus. The rocket ship leaves when the interim on the 184th event for the PACT trial is released in about 10 weeks. This will put it in lock step with ASCO. For those of us nibbling at the under-a-dollar prices, the train has left the station."I found plenty of reasons to be cautious about TNFerade, GenVec's gene therapy drug for pancreatic cancer, after the company released data from the first interim analysis of the phase III study in November 2008. I won't go over the details here because you can go back and read my analysis.
Biotech Stock Mailbag: GenVec
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.